ARQT · Arcutis Biotherapeutics, Inc.
$31.81
+1.96% last session
End-of-day data · close of 2026-10-26
Market cap
$4B
Enterprise value
$4B
Trailing P/E
144.6
Forward P/E
23.8
Dividend yield
0.0%
Beta
1.58
Avg volume
2M
Employees
0K
Daily Change %
1.96%
5 Days Change
-1.21%
10 Days Change
10.37%
30 Days Change
18.16%
60 Days Change
33.77%
Month to Day Change
25.78%
Year to Day Change
9.54%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ARQT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
Morgan Stanley
Overweight$38.00
+19.5% vs priceGoldman Sachs
Neutral$29.00
-8.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Guggenheim | Maintains | Buy | $38.00 → $44.00 |
| 2026-10-15 | Cantor Fitzgerald | Initiates | Overweight | $0.00 → $48.00 |
| 2026-08-06 | Morgan Stanley | Maintains | Overweight | $34.00 → $38.00 |
| 2026-08-06 | Guggenheim | Maintains | Buy | $35.00 → $38.00 |
| 2026-08-06 | Needham | Maintains | Buy | $36.00 → $40.00 |
| 2026-05-07 | Needham | Reiterates | Buy | $36.00 |
| 2026-03-02 | Mizuho | Maintains | Outperform | $37.00 → $35.00 |
| 2026-02-27 | Guggenheim | Maintains | Buy | $34.00 → $35.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 66 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 21.4% above the 50-day MA ($26.20).
- bullish: Price vs 200-day MA: Trading 26.5% above the 200-day MA ($25.15).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.52) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($32.82).
ARQT Price Chart
Loading chart for ARQT…
Fundamentals
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.